Cargando…
Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
INTRODUCTION: To determine visual and anatomical outcomes of diabetic macular oedema (DMO) patients in a tertiary centre following conversion to aflibercept having been refractory to previous treatment with bevacizumab/ranibizumab. METHODS: A retrospective case series of patients with a diagnosis of...
Autores principales: | McCloskey, Clare F., Mongan, Ann-Marie, Chetty, Shivona, McAteer, Darren M. J., Quinn, Shauna M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997601/ https://www.ncbi.nlm.nih.gov/pubmed/29508370 http://dx.doi.org/10.1007/s40123-018-0123-0 |
Ejemplares similares
-
Intravitreal aflibercept for treatment of macular oedema associated with immune recovery uveitis
por: Rothova, Aniki, et al.
Publicado: (2020) -
Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection
por: Fujii, Ayaka, et al.
Publicado: (2014) -
Retinal arteriolar oxygen saturation predicts the need for intravitreal aflibercept in patients with diabetic macular oedema
por: Blindbæk, Søren Leer, et al.
Publicado: (2020) -
Comment on: Ranibizumab and aflibercept intravitreal injection for treatment
naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020) -
Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomes
por: Sivaprasad, Sobha, et al.
Publicado: (2023)